Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-26

Clinical Trial Update: Aralast alpha1-proteinase Inhibitor Surveillance Study [Phase 4]

View source ↗

Summary

A Phase 4 surveillance study of Aralast alpha1-proteinase inhibitor in Alpha1-antitrypsin Deficiency was terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aralast (alpha-1 antitrypsin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alpha1-antitrypsin Deficiency | Phase 4 | Status: TERMINATED | Results posted: 2011-08-26